PMCB - PharmaCyte Biotech Earnings per share for the last twelve months

Graphic logo of PharmaCyte (PMCB)

PharmaCyte Biotech (PMCB) currently reports no revenue, as the development of bio-capsules for cancer therapy remains in the testing phase. On the GURU.Markets platform, the rolling earnings per share trend reflects a dynamic where this metric equals -2.40. The business relies on outsourced production via CMO facilities to minimize downtime risks. The innovative cell encapsulation platform creates potential for high pricing power in the future.

PMCB PharmaCyte Net earnings per share for the last 12 months (07/04/2022 - 11/11/2026)

PMCB (PharmaCyte Biotech Inc.): analytical breakdowns and indicator data

- share price and expert price forecast:
Stock Quotes PharmaCyte|PMCB - Analyst Forecast Prices
- market capitalization statistics:
Market Value PharmaCyte Biotech, Inc.|PMCB - Total Enterprise Value
- shareholders' equity book value data:
Net Assets per Single Share PharmaCyte Biotech|PMCB - Company Net Assets|Market Capitalization to Book Value Ratio pharmacyte.com|PMCB - Company Total Assets
- debt and liquidity details:
Total Debt to Capital PharmaCyte Biotech|PMCB - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital PharmaCyte|PMCB - Aggregate Debt Obligations|Debt to Book Capitalization Ratio PharmaCyte Biotech, Inc.|PMCB - Long-Term Liabilities|Company Short-Term Debts PharmaCyte Biotech|Quick Ratio pharmacyte.com
- earnings and multiples data:
PMCB - Net Profit|Expected Profit PharmaCyte Biotech|PMCB - Company Value to Net Income|Future Price to Earnings PharmaCyte|PMCB - Price/Earnings to Growth Multiple|EV/EBITDA Multiple PharmaCyte Biotech, Inc.|PMCB - Operating profit EBITDA|Net earnings per share (EPS TTM) PharmaCyte Biotech|PMCB - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months pharmacyte.com|PMCB - Earnings per share growth rate in current year|Expected earnings per share growth for next year PharmaCyte Biotech
General company analysis:PMCB - pharmacyte.com
Manufactured products of PharmaCyte Biotech Inc.

Net income per share over 12 months measures the portion of actual earnings attributable to a single common share. This metric allows for an assessment of real business efficiency by excluding the impact of the total issuance volume. By analyzing the current trailing 12-month earnings per share, an investor identifies the stability of equity income. For PharmaCyte Biotech (PMCB), this indicator reflects the financial results from the commercialization of cell encapsulation patents. The trend of this metric confirms the ability of biotechnological developments to generate capital through partnerships with pharma behemoths.

Key competitors

TLSI: Net earnings per share for the last 12 months|renovorx.com - Earnings per share for the last four quarters